EUVIMEDDescoperă EUVIMED
Crossref

EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors

Helena Estevão-Pereira, Catarina Guimarães-Teixeira, Bianca C T Flores, Filipa Moreira-Silva, Nuno Tiago Tavares, Rita Guimarães, Isaac Braga, Joaquina Maurício, Rui Henrique iD, Carmen Jerónimo, João Lobo iD

Andrology · 2025

DOI: 10.1111/andr.13604 ↗

At a glance

Journal article in Andrology, 2025. Written by Helena Estevão-Pereira and 10 co-authors. Institution: Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of…. Major MEDLINE topics: Enhancer of Zeste Homolog 2 Protein, Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Biomarkers, Tumor. Cited 4 times so far (Crossref); 57 references. Funded by: Fundação para a Ciência e a Tecnologia.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Testicular germ cell tumors remain the most frequent solid malignancies in young males. Despite excellent prognosis, the fact that only 60% of patients at diagnosis have elevated serum tumor markers (dependent on stage and histology) and the poor quality of life of patients who develop resistance to chemotherapy cannot be neglected. Consequently, it is mandatory to bring out novel biomarkers.

Objectives

The main goal was to evaluate EZH2 and EHMT2/G9a immunoexpression in a well‐characterized patients’ cohort of primary and metastatic testicular germ cell tumors, seeking associations with clinicopathological features and discovering differential immunoexpression patterns among specific subtypes. Materials and methods First, an in silico analysis of the Cancer Genome Atlas database was performed regarding EZH2 and EHMT2/G9a. Then, immunohistochemistry for EZH2 and EHMT2/G9a was carried out in a cohort of testicular germ cell tumor patients, comprising 155 chemo‐naïve primary tumors and 11 chemo‐treated metastases. Immunoexpression was evaluated using a digital pathology analysis software.

Results

Higher EZH2 and EHMT2/G9a expression levels were found in non‐seminoma in the in silico analysis, particularly in embryonal carcinoma. Through digital pathology analysis, non‐seminomas showed significantly higher EZH2 and EHMT2/G9a immunoexpression, with embryonal carcinoma showing higher expression. Moreover, mixed tumors with 50% or more of embryonal carcinoma component revealed the highest nuclei positivity for both biomarkers. Cisplatin‐exposed metastases demonstrated a higher EZH2‐positive nuclei and H ‐score, as well as higher EHMT2/G9a‐positive nuclei. Discussion and conclusion Overall, our data suggest that EZH2 and EHMT2/G9a might be associated with greater aggressiveness and, eventually, involved in the metastatic setting, paving the way for testing targeted therapies.

Subjects

MeSH terms (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinTesticular NeoplasmsNeoplasms, Germ Cell and EmbryonalBiomarkers, TumorHistone-Lysine N-MethyltransferaseHumansMaleAdultYoung AdultMiddle AgedAdolescentHistocompatibility Antigens

Author keywords

EHMT2/G9aEZH2biomarkerstesticular germ cell tumors

Substances

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanBiomarkers, TumorEHMT2 protein, humanHistone-Lysine N-MethyltransferaseHistocompatibility Antigens

Authors and institutions

  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Po…
  • Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
  • Department of Urology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
  • Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
  • Clinical Oncology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raque…
  • Department of Pathology and Molecular Immunology, ICBAS - School of Medicine & Biomedical Sciences, University of Porto, Porto, Portugal.

ORCID profiles: Rui Henrique, João Lobo

Funding

  • Fundação para a Ciência e a Tecnologia

Cite

APA

Estevão-Pereira, H., Guimarães-Teixeira, C., Flores, B. C. T., Moreira-Silva, F., Tavares, N. T., Guimarães, R., Braga, I., Maurício, J., Henrique, R., Jerónimo, C., & Lobo, J. (2025). EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors. Andrology. https://doi.org/10.1111/andr.13604

Vancouver

Estevão-Pereira H, Guimarães-Teixeira C, Flores BCT, Moreira-Silva F, Tavares NT, Guimarães R, et al. EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors. Andrology. 2025. doi:10.1111/andr.13604

BibTeX
@article{EstevoPereira2025,
  author = {Estevão-Pereira, Helena and Guimarães-Teixeira, Catarina and Flores, Bianca C T and Moreira-Silva, Filipa and Tavares, Nuno Tiago and Guimarães, Rita and Braga, Isaac and Maurício, Joaquina and Henrique, Rui and Jerónimo, Carmen and Lobo, João},
  title = {EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors},
  journal = {Andrology},
  year = {2025},
  doi = {10.1111/andr.13604}
}
Start for free →